Anti-VEGF Market Research Report Information By Product (Eylea, Lucentis, And Beovu), By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, And Age-Related Macular Degeneration) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Industry Forecast Till 2032

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3.Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2.Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitutes

5.2.5. Intensity of Bausch Health Companies Inc.

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Regional Impact

5.3.3. Opportunity and Threat Analysis

6. GLOBAL ANTI-VEGF MARKET, BY PRODUCT

6.1. Overview

6.2. Eylea

6.3. Lucentis

6.4. Beovu

7. GLOBAL ANTI-VEGF MARKET, BY DISEASE

7.1. Overview

7.2. Macular Edema

7.3. Diabetic Retinopathy

7.4. Retinal Vein Occlusion

7.5. Age-Related Macular Degeneration

8. GLOBAL ANTI-VEGF MARKET, BY REGION

8.1. Overview

8.1. North America

8.1.1. US

8.1.2. Canada

8.2. Europe

8.2.1. Germany

8.2.2. France

8.2.3. UK

8.2.4. Italy

8.2.5. Spain

8.2.6. Rest of Europe

8.3. Asia-Pacific

8.3.1. China

8.3.2. India

8.3.3. Japan

8.3.4. South Korea

8.3.5. Australia

8.3.6. Rest of Asia-Pacific

8.4. Rest of the World

8.4.1. Middle East

8.4.2. Africa

8.4.3. Latin America

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Global Anti-VEGF Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Global Anti-VEGF Market,

9.7. Key Developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Financial Matrix

9.8.1. Sales & Operating Income, 2023

9.8.2. Major Players R&D Expenditure. 2023

10. COMPANY PROFILES

10.1. Regeneron Pharmaceuticals

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Products Offered

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Novartis AG

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Products Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Roche

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Products Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Bayer AG

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Products Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Allergan plc

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Products Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Pfizer Inc.

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Products Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Bausch Health Companies Inc.

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Products Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

10.8. AbbVie Inc.

10.8.1. Company Overview

10.8.2. Financial Overview

10.8.3. Products Offered

10.8.4. Key Developments

10.8.5. SWOT Analysis

10.8.6. Key Strategies

10.9. SANTEN PHARMACEUTICAL CO., LTD.

10.9.1. Company Overview

10.9.2. Financial Overview

10.9.3. Products Offered

10.9.4. Key Developments

10.9.5. SWOT Analysis

10.9.6. Key Strategies

10.10. Alcon Inc.

10.10.1. Company Overview

10.10.2. Financial Overview

10.10.3. Products Offered

10.10.4. Key Developments

10.10.5. SWOT Analysis

10.10.6. Key Strategies

11. APPENDIX

11.1. References

11.2. Related Reports

LIST OF TABLES

TABLE 1 GLOBAL ANTI-VEGF MARKET, SYNOPSIS, 2019-2032

TABLE 2 GLOBAL ANTI-VEGF MARKET, ESTIMATES & FORECAST, 2019-2032 (USD BILLION)

TABLE 3 GLOBAL ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 4 GLOBAL ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 5 NORTH AMERICA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 6 NORTH AMERICA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 7 US: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 8 US: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 9 CANADA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 10 CANADA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 1 EUROPE: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 2 EUROPE: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 3 GERMANY: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 4 GERMANY: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 5 FRANCE: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 6 FRANCE: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 7 ITALY: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 8 ITALY: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 9 SPAIN: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 10 SPAIN: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 11 UK: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 12 UK: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 13 REST OF EUROPE: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 14 REST OF EUROPE: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 15 ASIA-PACIFIC: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 16 ASIA-PACIFIC: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 17 JAPAN: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 18 JAPAN: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 19 CHINA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 20 CHINA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 21 INDIA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 22 INDIA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 23 AUSTRALIA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 24 AUSTRALIA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 25 SOUTH KOREA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 26 SOUTH KOREA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 27 REST OF ASIA-PACIFIC: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 28 REST OF ASIA-PACIFIC: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 29 REST OF THE WORLD: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 30 REST OF THE WORLD: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 31 MIDDLE EAST: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 32 MIDDLE EAST: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 33 AFRICA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 34 AFRICA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

TABLE 35 LATIN AMERICA: ANTI-VEGF MARKET, BY PRODUCT, 2019-2032 (USD BILLION)

TABLE 36 LATIN AMERICA: ANTI-VEGF MARKET, BY DISEASE, 2019-2032 (USD BILLION)

LIST OF FIGURES

FIGURE 1 RESEARCH PROCESS

FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL ANTI-VEGF MARKET

FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL ANTI-VEGF MARKET

FIGURE 4 GLOBAL ANTI-VEGF MARKET, SHARE (%), BY PRODUCT, 2023

FIGURE 5 GLOBAL ANTI-VEGF MARKET, SHARE (%), BY DISEASE, 2023

FIGURE 6 GLOBAL ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 7 NORTH AMERICA: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 8 EUROPE: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 9 ASIA-PACIFIC: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 10 REST OF THE WORLD: ANTI-VEGF MARKET, SHARE (%), BY REGION, 2023

FIGURE 11 GLOBAL ANTI-VEGF MARKET: COMPANY SHARE ANALYSIS, 2023 (%)

FIGURE 12 REGENERON PHARMACEUTICALS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 13 REGENERON PHARMACEUTICALS: SWOT ANALYSIS

FIGURE 14 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 15 NOVARTIS AG: SWOT ANALYSIS

FIGURE 16 ROCHE: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 17 ROCHE: SWOT ANALYSIS

FIGURE 18 BAYER AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 19 BAYER AG: SWOT ANALYSIS

FIGURE 20 ALLERGAN PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 21 ALLERGAN PLC: SWOT ANALYSIS

FIGURE 22 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 23 PFIZER INC.: SWOT ANALYSIS

FIGURE 24 BAUSCH HEALTH COMPANIES INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 25 BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS

FIGURE 26 ABBVIE INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 27 ABBVIE INC.: SWOT ANALYSIS

FIGURE 28 SANTEN PHARMACEUTICAL CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 SANTEN PHARMACEUTICAL CO., LTD.: SWOT ANALYSIS

FIGURE 30 ALCON INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 ALCON INC.: SWOT ANALYSIS